Jump to content

Developing Countries Vaccine Manufacturers Network

Add links
From Wikipedia, the free encyclopedia
DCVMN International
(Developing Countries Vaccine Manufacturers Network)
Formation2000; 25 years ago
Legal statusNon-profit organization
PurposeVaccine equity
HeadquartersNyon, Switzerland
CEO
Rajinder Suri
Websitehttps://dcvmn.org/

The Developing Countries Vaccine Manufacturers Network (DCVMN International) is a voluntary non-partisan public health alliance of health organizations and vaccine manufacturers. DCVMN aims to protect people globally against known and emerging infectious diseases through the provision of a consistent supply of high quality vaccines at affordable prices for developing countries, to achieve vaccine equity.[1][2][3] DCVMN includes many It was established in 2000[4]/2001,[5] and is headquartered in Switzerland.[4]

Over the past quarter century, DCVMN has grown and transformed, becoming stronger and larger than ever in its capacity to fulfill this mission. Today, DCVMN remains unwavering in its purpose, empowering vaccine manufacturers across the developing world to provide high-quality, affordable vaccines on a global scale.

DCVMN International stands as the largest public health-driven alliance of vaccine manufacturers from developing countries. Through advocacy, professional training programs, and technology transfer initiatives, it strengthens the capacity of members companies to advance in innovation and technological expertise. As a catalyst for partnerships and funding, DCVMN also fosters vital collaborations, helping to expand vaccine accessibility to communities everywhere. DCVMN's commitment to public health is further reflected in its role as an educator, informing the public on the importance of vaccines.

As of 2025, DCVMN International is a global force comprising over 48 public and private manufacturers across 17 countries and territories in Africa, Asia, Europe, the Middle East, and Latin America. Together, its members possess the comprehensive capabilities required for research, development, manufacturing, and worldwide distribution of vaccines. During the COVID-19 Pandemic, DCVMN members supplied more than 60% of the global vaccine supply of COVID-19 vacccines, with 8 different vaccine technology platforms used to develop these vaccines between all of the 20 members that are engaging in the COVID-19 vaccine effort. DCVMN members reported that they had the capability to supply over 400 distinct vaccine products to 170 countries, more than 100 of these vaccines have WHO Prequalification, totalling more than 6 billion vaccine doses annually.[6]

Members are developing and producing novel vaccines for illnesses including neglected tropical diseases:[7] rotavirus, Japanese encephalitis, pertussis,[8] haemophilus influenzae, hepatitis B,[9] hepatitis E, meningitis A,[3] cholera, poliovirus, human papillomavirus infection, dengue fever, Chikungunya virus and COVID-19.[6][10]

The DCVMN is active in identifying obstacles in the processes of vaccine registration and use. It works to increase coordination of requirements and procedures to improve the prequalification, procurement and supply of vaccines. This can involve governments in different countries, the World Health Organization (WHO), and United Nations agencies such as UNICEF.[11][12][13]

The Developing Countries Vaccine Manufacturers Network has received funding from the Bill & Melinda Gates Foundation.[4]

DCVMN International is registered as a legal entity under Swiss jurisdiction, operating under Articles 60 and beyond of the Swiss Civil Code. While the DCVMN headquarters are anchored in Switzerland, the CEO's office is based in India, strategically positioning their leadership to respond to the needs of developing nations worldwide.

Areas of Work

[edit]

Advocacy

[edit]

DCVMN discerns the requirements of its members and serves as their spokesperson in international gatherings and discussions with influential organizations like WHO, UNICEF, GAVI, PATH, and forums such as the G20. DCVMN's aim is to ensure that the voices of developing countries' vaccine manufacturers (DCVMs) are not only heard but also respected and duly considered. DCVMN advocates for the interests of its members, engaging in negotiations to maintain affordability while striving to secure a larger portion of the funding pool and marking its members as the main vaccine suppliers to organization like UNICEF and Gavi.

In the recent years, DCVMN has significantly elevated its presence on the global stage, with the CEO taking an active role in numerous high-profile conferences and forums. From leading discussions at key industry events to participating in prestigious gatherings with major stakeholders, such as global health organizations, government representatives, and industry leaders, DCVMN is increasingly recognized as a vital voice in the vaccine field. Its invitation to these renowned conferences is a testament to its growing influence and credibility in driving vaccine equity and innovation.

For our sponsors, this enhanced visibility means greater exposure and association with an organization that is not only shaping global health agendas but also connecting with the most influential leaders in the sector. By partnering with DCVMN, sponsors gain a front-row seat amplifying their brand among top-tier decision-makers and stakeholders dedicated to making a lasting impact on global public health.

Vaccine Workforce Development

[edit]

For DCVMN, strengthening the capabilities of vaccine manufacturers goes beyond technology, it starts with the workforce. To ensure that its members remain agile, innovative, and aligned with global standards, they developed a comprehensive portfolio of training initiatives designed to build a skilled and future-ready workforce. From self-paced online courses and immersive virtual reality simulations to hands-on workshops and technology transfer programs, its training ecosystem supports continuous professional development across every level of vaccine production.

Whether enhancing technical know-how, guiding regulatory navigation, or empowering regional trainers in developing countries, DCVMN is committed to equipping manufacturers with the tools and knowledge needed to meet today’s challenges and tomorrow’s demands in vaccine development and delivery.

Liason

[edit]

DCVMN actively fosters collaborations and partnerships between its members and leading international organizations. As a vital intermediary, DCVMN leverages its extensive network to create opportunities for its members to secure funding and engage in strategic technology and business partnerships. This proactive approach positions DCVMN as a trusted partner in the global health landscape that supports quality and reliable vaccine manufacturers.

Acting as a bridge, DCVMN disseminates crucial information in the field of global public health to its members, including details about funding opportunities, invitations to meetings, policy shifts in global health, and prospects for partnerships. Additionally, DCVMN enhances the visibility of its members by showcasing their achievements on its website and social media channels.

DCVMN members have the opportunity to actively participate in DCVMN sub-committees and serve as representatives in the boards, committees, advisory groups, forums, and task forces of international organizations collaborating with DCVMN such as WHO, Gavi and UNICEF. Additionally, DCVMN has 6 expert Working Groups (WGs) where members convene regularly to share best practices and collaborate on projects of mutual interest.

Annual General Meeting

[edit]

The DCVMN Annual General Meeting (AGM) serves as a distinguished gathering, bringing together leaders from member companies, global health organizations, governments, academia, and industry experts under one roof. It serves as a nexus for exploring potential collaborations and partnerships, while also delving into the latest advancements in policy, and technology related to vaccines.

Every year, one of DCVMN's member companies co.hosts this event. With over 400 delegates in attendance, the AGM spans three days of illuminating presentations, lively discussions, and invaluable networking opportunities for members, sponsors, and resource members alike. The AGM takes place in the last quarter of each year.

Prominent figures in the vaccine field are regular attendees at our AGM, including notable individuals like Dr. Tedros Ghebreyesus, Director-General of WHO, Dr. Richard Hatchett, CEO of CEPI, and Dr. Jarbas Barbosa, Director of PAHO.

The AGM offers a unique platform to explore critical vaccine topics, from manufacturing in Africa to innovative technologies, while enabling members to connect directly with peers, international organizations, and sponsors.

References

[edit]
  1. ^ "DCVMN". Developing Countries Vaccine Manufacturers Network. Retrieved 26 April 2022.
  2. ^ Poeloengan, Thamrin; Raw, Isaias; Martinez, Luis Herrera; El-Abbadi, Mohamed (12 November 2001). "Developing Country Vaccine Manufacturers Network (DCVMN), 26–27 April 2001, Bandung, Indonesia". Vaccine. 20 (3): 285–287. doi:10.1016/S0264-410X(01)00333-4. ISSN 0264-410X. PMID 11672886. Retrieved 26 April 2022.
  3. ^ a b Pagliusi, Sonia; Makhoana, Morena; Datla, Mahima; Leite, Luciana; Hendriks, Jan; Gholami, Alireza; Huang, Weidan; Gao, Yongzhong; Jadhav, Suresh; Harshavardhan, Gutla V. J. A.; Wu, Yonglin; Suhardono, Mahendra; Homma, Akira (28 June 2013). "Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012". Vaccine. 31 (31): 3111–3115. doi:10.1016/j.vaccine.2013.04.082. ISSN 1873-2518. PMID 23684836. Retrieved 26 April 2022.
  4. ^ a b c "Developing Countries Vaccine Manufactures Network (DCVMN) International". Devex. Retrieved 26 April 2022.
  5. ^ Hendriks, Jan; Blume, Stuart (7 July 2016). "Why might regional vaccinology networks fail? The case of the Dutch-Nordic Consortium". Globalization and Health. 12 (1): 38. doi:10.1186/s12992-016-0176-6. ISSN 1744-8603. PMC 4936226. PMID 27388678.
  6. ^ a b Hayman, Benoit; Dennehy, Maureen (23 August 2021). "Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization". Vaccine. 39 (36): 5153–5161. doi:10.1016/j.vaccine.2021.07.044. ISSN 1873-2518. PMC 8330991. PMID 34362602.
  7. ^ Jadhav, S.; Gautam, M.; Gairola, S. (May 2014). "Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices". Clinical Microbiology and Infection. 20: 37–44. doi:10.1111/1469-0691.12568. PMID 24476201. Retrieved 26 April 2022.
  8. ^ Pagliusi, Sonia; Leite, Luciana C.C.; Datla, Mahima; Makhoana, Morena; Gao, Yongzhong; Suhardono, Mahendra; Jadhav, Suresh; Harshavardhan, Gutla V.J.A.; Homma, Akira (April 2013). "Developing Countries Vaccine Manufacturers Network: Doing good by making high-quality vaccines affordable for all" (PDF). Vaccine. 31: B176 – B183. doi:10.1016/j.vaccine.2012.11.060. PMID 23598479. Retrieved 27 April 2022.
  9. ^ Jadhav, Suresh; Datla, Mahima; Kreeftenberg, Hans; Hendriks, Jan (20 March 2008). "The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries". Vaccine. 26 (13): 1611–1615. doi:10.1016/j.vaccine.2008.01.034. ISSN 0264-410X. PMID 18294742. Retrieved 26 April 2022.
  10. ^ Pagliusi, Sonia; Jarrett, Stephen; Hayman, Benoit; Kreysa, Ulrike; Prasad, Sai D.; Reers, Martin; Hong Thai, Pham; Wu, Ke; Zhang, Youn Tao; Baek, Yeong Ok; Kumar, Anand; Evtushenko, Anatoly; Jadhav, Suresh; Meng, Weining; Dat, Do Tuan; Huang, Weidan; Desai, Samir (22 July 2020). "Emerging manufacturers engagements in the COVID −19 vaccine research, development and supply". Vaccine. 38 (34): 5418–5423. doi:10.1016/j.vaccine.2020.06.022. ISSN 0264-410X. PMC 7287474. PMID 32600908.
  11. ^ Dellepiane, Nora; Pagliusi, Sonia (21 May 2019). "Opportunities for improving access to vaccines in emerging countries through efficient and aligned registration procedures: An industry perspective". Vaccine. 37 (23): 2982–2989. doi:10.1016/j.vaccine.2019.03.025. ISSN 0264-410X. PMID 31027928. S2CID 135439603.
  12. ^ Dellepiane, Nora; Pagliusi, Sonia (7 June 2018). "Challenges for the registration of vaccines in emerging countries: Differences in dossier requirements, application and evaluation processes". Vaccine. 36 (24): 3389–3396. doi:10.1016/j.vaccine.2018.03.049. ISSN 0264-410X. PMC 6278877. PMID 29724510.
  13. ^ Hayman, Benoit; Bowles, Alex; Evans, Beth; Eyermann, Elizabeth; Nepomnyashchiy, Lyudmila; Pagliusi, Sonia (22 February 2021). "Advancing innovation for vaccine manufacturers from developing countries: Prioritization, barriers, opportunities". Vaccine. 39 (8): 1190–1194. doi:10.1016/j.vaccine.2020.12.085. ISSN 0264-410X. PMC 7909323. PMID 33487466. Retrieved 26 April 2022.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Developing_Countries_Vaccine_Manufacturers_Network&oldid=1294126947"